title: Relationship between preheparin lipoprotein lipase mass concentration in serum and bare metal stent restenosis.
abstract: OBJECTIVE
  Insulin resistance or inflammation is known to be related with lipoprotein lipase activity and these factors are also closely associated with the pathogenesis of bare-metal stent restenosis. This study examined the relationship between preheparin lipoprotein lipase protein (preheparin LpL mass) concentration in serum and bare-metal stent restenosis.
  
  
  METHODS
  A total of 121 lesions in 112 patients who underwent bare-metal stent implantation using NIR stent or S660/670 stent were examined. Subjects were divided into two groups (N group; patients with normal preheparin LpL mass concentration, n = 50 or L group; patients with low preheparin LpL mass concentration, n = 71) according to the mean levels of preheparin LpL mass concentration (male 39.3 ng/ml, female 50.6 ng/ml).
  
  
  RESULTS
  There were no differences in percutaneous coronary intervention or angiographical characteristics. The L group had a significantly higher incidence of restenosis rate and target lesion revascularization than the N group (N group vs L group: 8.0% vs 42.3%, p < 0.0001; 8.0% vs 33.8%, p = 0.0008, respectively). Homeostatic model assessment of insulin resistance as a marker of insulin resistance and high sensitive C-reactive protein concentration were significantly higher in the L group than the N group. Multiple regression analysis showed that only low preheparin LpL mass concentration was an independent factor for restenosis (t value = 3.6, p = 0.0005).
  
  
  CONCLUSIONS
  Preheparin LpL mass concentration is closely associated with bare-metal stent restenosis and preheparin LpL mass concentration may be an important marker for the selection of bare-metal stent or drug-eluting stent.
authors.affiliation: Division of Internal Medicine, Sakura Hospital, Toho University School of Medicine, Chiba. thitsu@jcom.home.ne.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Hitsumoto
authors.forename: Mao
authors.initials: M
authors.lastname: Takahashi
authors.forename: Takuo
authors.initials: T
authors.lastname: Iizuka
authors.forename: Kohji
authors.initials: K
authors.lastname: Shirai
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood* / Q000201:enzymology / Q000628:therapy; D023903:Coronary Restenosis / Q000097:blood* / Q000201:enzymology; D005260:Female; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007333:Insulin Resistance; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008297:Male; D008670:Metals; D008875:Middle Aged; D011956:Receptors, Cell Surface / Q000097:blood*; D012044:Regression Analysis; D012307:Risk Factors; D015607:Stents
chemical_list: D015415:Biomarkers; C484074:LPL binding proteins, human; D008670:Metals; D011956:Receptors, Cell Surface; D006493:Heparin; D002097:C-Reactive Protein; D008071:Lipoprotein Lipase